PolyNovo (ASX:PNV) Insider Acquires A$28,080.00 in Stock

PolyNovo Limited (ASX:PNV) insider Leon Hoare acquired 30,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The shares were bought at an average cost of A$0.94 per share, with a total value of A$28,080.00.

PolyNovo Price Performance

The company has a debt-to-equity ratio of 21.32, a quick ratio of 1.58 and a current ratio of 3.41. The firm has a market capitalization of $1.30 billion, a PE ratio of 247.31, a P/E/G ratio of 2.63 and a beta of 1.67.

PolyNovo Company Profile

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.